当前位置： SCI文献检索 > ALIMENTARY PHARMACOLOGY & THERAPEUTICS期刊下所有文献 > The impact of hepatitis C burden: an evidence-based approach.

The impact of hepatitis C burden: an evidence-based approach.

Abstract：

BACKGROUND:Infection with the hepatitis C virus (HCV) has been considered a major cause of mortality, morbidity and resource utilisation in the US. In addition, HCV is the main cause of hepatocellular cancer (HCC) in the US. Recent developments in the diagnosis and treatment of HCV, including new recommendations pertaining to screening for HCV by the Centers for Disease Control and Prevention and newer treatment regimens with high efficacy, short duration and the potential for interferon-free therapies, have energised the health care practitioners regarding HCV management. AIM:To assess the full impact of HCV burden on clinical, economic and patient-reported outcomes. METHODS:An expert panel was convened to assess the full impact of HCV burden on a number of important outcomes using an evidence-based approach predicated on Grading of Recommendations Assessment, Development and Evaluation methodology. The literature was summarised, graded using an evidence-based approach and presented during the workshop. Workshop presentations were intended to review recent, relevant evidence-based literature and provide graded summary statements pertaining to HCV burden on topics including the relationships between HCV and the development of important outcomes. RESULTS:The associations of HCV with cirrhosis, HCC, liver-related mortality, type 2 diabetes mellitus, rheumatological diseases and quality of life impairments are supported by strong evidence. Also, there is strong evidence that sustained viral eradication of HCV can improve important outcomes such as mortality and quality of life. CONCLUSIONS:The current evidence suggests that HCV has been associated with tremendous clinical, economic and quality of life burden.

journal_name

Aliment Pharmacol Ther

journal_title

Alimentary pharmacology & therapeutics

authors

Younossi ZM,Kanwal F,Saab S,Brown KA,El-Serag HB,Kim WR,Ahmed A,Kugelmas M,Gordon SC

doi

10.1111/apt.12625

subject

Has Abstract

pub_date

2014-03-01 00:00:00

pages

518-31

issue

5

eissn

0269-2813

issn

1365-2036

journal_volume

39

pub_type

杂志文章

相关文献

ALIMENTARY PHARMACOLOGY & THERAPEUTICS文献大全
  • Helicobacter pylori eradication: proton pump inhibitor vs. ranitidine bismuth citrate plus two antibiotics for 1 week-a meta-analysis of efficacy.

    abstract：OBJECTIVE:To compare the efficacy of proton pump inhibitor vs. ranitidine bismuth citrate (RBC) with two antibiotics for 1 week in Helicobacter pylori eradication. METHODS:Randomized trials comparing 1-week regimens with (i) proton pump inhibitor plus two antibiotics [clarithromycin (C) and amoxycillin (A) or a nitroi...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,meta分析

    doi：10.1046/j.1365-2036.2000.00809.x

    authors： Gisbert JP,González L,Calvet X,Roqué M,Gabriel R,Pajares JM

    更新日期：2000-09-01 00:00:00

  • The effect of trospium chloride on oesophageal motility.

    abstract：:Trospium chloride is a muscarinergic antagonist acting on oesophageal smooth muscle and on ganglionic and/or myenteric neurons. The effect of this drug on oesophageal motility was tested in 16 healthy male subjects in a double-blind randomized cross-over examination of trospium chloride or placebo following phentolami...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1111/j.1365-2036.1993.tb00072.x

    authors： Frieling T,Enck P,Dohmann R,Wienbeck M,Lübke HJ

    更新日期：1993-02-01 00:00:00

  • Microbial translocation and T cell activation are modified by direct-acting antiviral therapy in HCV-infected patients.

    abstract：BACKGROUND:Microbial translocation from the gut lumen has been involved in the pathogenesis of liver damage in hepatitis C virus (HCV) infection. AIM:To investigate the impact of direct-acting antiviral treatment on microbial translocation and T-cell activation, in patients with hepatitis C-related liver disease. MET...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/apt.14994

    authors： Lattanzi B,Baroncelli S,De Santis A,Galluzzo CM,Mennini G,Michelini Z,Lupo M,Ginanni Corradini S,Rossi M,Palmisano L,Merli M

    更新日期：2018-11-01 00:00:00

  • Oral or intravenous erythromycin has no effect on human distal colonic motility.

    abstract：:Erythromycin is a prokinetic agent for the lower oesophageal sphincter, the stomach, the gallbladder and the small bowel, acting directly on motilin receptors. Its effect on pressure activity of the human colon has not been investigated. Eight healthy volunteers were studied on 2 occasions and given intravenous or ora...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1111/j.1365-2036.1992.tb00573.x

    authors： Jameson JS,Rogers J,Misiewicz JJ,Raimundo AH,Henry MM

    更新日期：1992-10-01 00:00:00

  • Erythromycin prior to endoscopy for acute upper gastrointestinal haemorrhage: a cost-effectiveness analysis.

    abstract：BACKGROUND:Erythromycin is a potent stimulator of gastrointestinal motility. Recent studies have examined the use of intravenous erythromycin to clear the stomach of blood before oesophago-gastroduodenoscopy (EGD) for acute upper gastrointestinal haemorrhage (UGIH). These studies have shown clinical effectiveness. AIM...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,评审

    doi：10.1111/j.1365-2036.2007.03516.x

    authors： Winstead NS,Wilcox CM

    更新日期：2007-11-15 00:00:00

  • Treatment of ulcerative colitis with germinated barley foodstuff feeding: a pilot study.

    abstract：BACKGROUND:Germinated barley foodstuff (GBF) has been shown to attenuate intestinal injury in animal models, largely by increasing luminal short-chain fatty acid production. AIM:To investigate the safety and efficacy of GBF in the treatment of ulcerative colitis (UC). METHODS:Ten patients with active UC received 30 g...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 临床试验,杂志文章

    doi：10.1046/j.1365-2036.1998.00432.x

    authors： Mitsuyama K,Saiki T,Kanauchi O,Iwanaga T,Tomiyasu N,Nishiyama T,Tateishi H,Shirachi A,Ide M,Suzuki A,Noguchi K,Ikeda H,Toyonaga A,Sata M

    更新日期：1998-12-01 00:00:00

  • The DU-MACH study: eradication of Helicobacter pylori and ulcer healing in patients with acute duodenal ulcer using omeprazole based triple therapy.

    abstract：AIM:To investigate the efficacy of two omeprazole triple therapies for the eradication of Helicobacter pylori, ulcer healing and ulcer relapse during a 6-month treatment-free period in patients with active duodenal ulcer. METHODS:This was a double-blind, randomized study in 15 centres across Canada. Patients (n = 149)...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 临床试验,杂志文章,多中心研究,随机对照试验

    doi：10.1046/j.1365-2036.1999.00471.x

    authors： Zanten SJ,Bradette M,Farley A,Leddin D,Lind T,Unge P,Bayerdörffer E,Spiller RC,O'Morain C,Sipponen P,Wrangstadh M,Zeijlon L,Sinclair P

    更新日期：1999-03-01 00:00:00

  • Comparative study of characteristics and disease management between subjects with frequent and occasional gastro-oesophageal reflux symptoms.

    abstract：BACKGROUND:Little is known about the distinctive characteristics of subjects with frequent (at least weekly) and occasional gastro-oesophageal reflux symptoms. AIM:To compare the characteristics and disease management of subjects complaining of at least weekly and less frequent gastro-oesophageal reflux symptoms. MET...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/j.1365-2036.2006.02811.x

    authors： Bretagne JF,Honnorat C,Richard-Molard B,Caekaert A,Barthélemy P

    更新日期：2006-03-01 00:00:00

  • Endoscopic ablation of Barrett's oesophagus: a randomized-controlled trial of photodynamic therapy vs. argon plasma coagulation.

    abstract：BACKGROUND:Barrett's oesophagus is the major risk factor for oesophageal adenocarcinoma. 5-Aminlevulinic acid-induced photodynamic therapy and argon plasma coagulation have been shown to be effective for ablating Barrett's oesophagus, but a comparative trial of these two modalities has not been reported. AIMS:To compa...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1111/j.1365-2036.2004.02277.x

    authors： Kelty CJ,Ackroyd R,Brown NJ,Stephenson TJ,Stoddard CJ,Reed MW

    更新日期：2004-12-01 00:00:00

  • Clarithromycin-amoxycillin therapy for Helicobacter pylori infection.

    abstract：BACKGROUND:More convenient therapies are needed to treat Helicobacter pylori infection successfully. Clarithromycin and amoxycillin are effective against H. pylori both in vivo and in vitro. Recent success with a high dose amoxycillin-metronidazole combination therapy led us to evaluate clarithromycin-amoxycillin dual ...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 临床试验,杂志文章

    doi：10.1111/j.1365-2036.1994.tb00313.x

    authors： al-Assi MT,Genta RM,Karttunen TJ,Graham DY

    更新日期：1994-08-01 00:00:00

  • Is the subjective perception of lactose intolerance influenced by the psychological profile?

    abstract：BACKGROUND:Symptoms of lactose intolerance are often attributed to lactose malabsorption but, as this relationship has not been demonstrated when a small dose of lactose similar to that contained in one cup of milk is ingested by intolerant patients, psychological factors may play a role in altered symptom perception. ...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/apt.12006

    authors： Tomba C,Baldassarri A,Coletta M,Cesana BM,Basilisco G

    更新日期：2012-10-01 00:00:00

  • Identifying responders to acid suppression in dyspepsia using a random starting day trial.

    abstract：BACKGROUND:Functional dyspepsia is a heterogeneous condition and a uniform response to drug treatment is not likely. This may be the reason for the general failure of acid suppression in clinical trials in these patients. It may be more rewarding to identify true responders to drug treatment by a single subject trial. ...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1046/j.1365-2036.2000.00866.x

    authors： Bytzer P,Hansen JM,Rune S,Bonnevie O,Breinstrup H,Funch-Jensen P,Matzen P,Meineche-Schmidt V,Schaffalitzky De Muckadell OB

    更新日期：2000-11-01 00:00:00

  • Clinical trial: vitamin D3 treatment in Crohn's disease - a randomized double-blind placebo-controlled study.

    abstract：BACKGROUND:Vitamin D has immune-regulatory functions in experimental colitis, and low vitamin D levels are present in Crohn's disease. AIM:To assess the effectiveness of vitamin D3 treatment in Crohn's disease with regard to improved disease course. METHODS:We performed a randomized double-blind placebo-controlled tr...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1111/j.1365-2036.2010.04355.x

    authors： Jørgensen SP,Agnholt J,Glerup H,Lyhne S,Villadsen GE,Hvas CL,Bartels LE,Kelsen J,Christensen LA,Dahlerup JF

    更新日期：2010-08-01 00:00:00

  • Review article: Effector role of epithelia in inflammation--interaction with bacteria.

    abstract：:The common response to infection is infiltration of the affected tissue by inflammatory cells. It is now recognized that the epithelium plays a crucial role in this immunological process by producing an array of proinflammatory cytokines including interleukin-8, tumour necrosis factor-alpha, monocyte chemotactic prote...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,评审

    doi：10.1111/j.1365-2036.1997.tb00810.x

    authors： Hecht G,Savkovic SD

    更新日期：1997-12-01 00:00:00

  • Does co-treatment with immunosuppressors improve outcome in patients with Crohn's disease treated with adalimumab?

    abstract：BACKGROUND:There is clear benefit from combination therapy with infliximab and immunosuppressive drugs (IS), but few data are available for adalimumab (ADA). AIM:To assess the efficacy of ADA monotherapy and ADA+IS for induction and maintenance therapy in Crohn's disease. METHODS:Retrospective study of patients with ...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/apt.12076

    authors： Reenaers C,Louis E,Belaiche J,Seidel L,Keshav S,Travis S

    更新日期：2012-12-01 00:00:00

  • Optimised infliximab monotherapy is as effective as optimised combination therapy, but is associated with higher drug consumption in inflammatory bowel disease.

    abstract：BACKGROUND:Combination treatment with azathioprine for 6-12 months is the preferred strategy for starting infliximab due to improved pharmacokinetics. However, optimised infliximab monotherapy with proactive dose escalations in case of low trough levels is a safer but under-studied alternative. AIM:To compare the clin...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/apt.15179

    authors： Drobne D,Kurent T,Golob S,Švegl P,Rajar P,Hanžel J,Koželj M,Novak G,Smrekar N,Ferkolj I,Štabuc B

    更新日期：2019-04-01 00:00:00

  • Colonic delivery of 4-aminosalicylic acid using amylose-ethylcellulose-coated hydroxypropylmethylcellulose capsules.

    abstract：BACKGROUND:4-Aminosalicylic acid has the potential for use in the treatment of diseases of the colon. AIM:To assess the feasibility of delivering 4-aminosalicylic acid directly to the colon using a hydroxypropylmethylcellulose capsule coated with a mixture of amylose, a polysaccharide metabolized by bacterial enzymes ...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1046/j.1365-2036.2002.01327.x

    authors： Tuleu C,Basit AW,Waddington WA,Ell PJ,Newton JM

    更新日期：2002-10-01 00:00:00

  • Effect of omeprazole and feeding on plasma gastrin in patients with achlorhydria.

    abstract：BACKGROUND:The mechanism of hypergastrinaemia during omeprazole therapy is unclear, but is generally assumed to be entirely a consequence of acid suppression. However, direct stimulation of G cells by omeprazole could also be a factor. In order to further investigate the mechanism of omeprazole-induced hypergastrinaemi...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/j.1365-2036.1995.tb00413.x

    authors： Banerjee S,Ardill JE,Beattie AD,McColl KE

    更新日期：1995-10-01 00:00:00

  • Night-time intra-oesophageal bile and acid: a comparison between gastro-oesophageal reflux disease patients who failed and those who were treated successfully with a proton pump inhibitor.

    abstract：BACKGROUND:Little is known about the contribution of bile and acid reflux to night-time symptoms generation in patients who failed PPI treatment. AIM:To compare the degree of night-time oesophageal acid and bile [by the surrogate duodenogastroesophageal reflux (DGER)] exposure between gastro-oesophageal reflux disease...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/j.1365-2036.2011.04583.x

    authors： Hershcovici T,Jha LK,Cui H,Powers J,Fass R

    更新日期：2011-04-01 00:00:00

  • Higher plasma vitamin D is associated with reduced risk of Clostridium difficile infection in patients with inflammatory bowel diseases.

    abstract：BACKGROUND:Patients with inflammatory bowel diseases (IBD) have an increased risk of clostridium difficile infection (CDI). Cathelicidins are anti-microbial peptides that attenuate colitis and inhibit the effect of clostridial toxins. Plasma calcifediol [25(OH)D] stimulates production of cathelicidins. AIM:To examine ...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,多中心研究

    doi：10.1111/apt.12706

    authors： Ananthakrishnan AN,Cagan A,Gainer VS,Cheng SC,Cai T,Szolovits P,Shaw SY,Churchill S,Karlson EW,Murphy SN,Kohane I,Liao KP

    更新日期：2014-05-01 00:00:00

  • Market share and costs of biologic therapies for inflammatory bowel disease in the USA.

    abstract：BACKGROUND:Real-world data quantifying the costs of increasing use of biologics in inflammatory bowel disease (IBD) are unknown. AIM:To determine the outpatient IBD drug utilization trends, relative market share, and costs in the USA during a 9-year period. METHODS:The Truven MarketScan® Database was analysed for pat...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/apt.14430

    authors： Yu H,MacIsaac D,Wong JJ,Sellers ZM,Wren AA,Bensen R,Kin C,Park KT

    更新日期：2018-02-01 00:00:00

  • The prevalence of inflammatory sacroiliitis assessed on magnetic resonance imaging of inflammatory bowel disease: a retrospective study performed on 186 patients.

    abstract：BACKGROUND:Magnetic resonance imaging (MRI) colonography or enterography is increasingly used to assess disease activity and complications in inflammatory bowel disease (IBD). However, no study has evaluated the role of this imaging technique to assess sacroiliitis. AIM:The primary objective was to assess the prevalen...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/apt.12680

    authors： Leclerc-Jacob S,Lux G,Rat AC,Laurent V,Blum A,Chary-Valckenaere I,Peyrin-Biroulet L,Loeuille D

    更新日期：2014-05-01 00:00:00

  • Review article: tegaserod -- the global experience.

    abstract：:Studies from the Western hemisphere have established the efficacy and safety of tegaserod in women with irritable bowel syndrome and constipation. This review summarizes the results of recent studies from around the world that confirm the efficacy and safety of tegaserod, and expand our understanding of the role of th...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,评审

    doi：10.1111/j.1365-2036.2004.02181.x

    authors： Chey WD

    更新日期：2004-11-01 00:00:00

  • Use of acid-suppressive therapy before anti-reflux surgery in 2922 patients: a nationwide register-based study in Denmark.

    abstract：BACKGROUND:Guidelines recommend that patients with gastro-oesophageal reflux disease are adequately treated with acid-suppressive therapy before undergoing anti-reflux surgery. Little is known of the use of acid-suppressive drugs before anti-reflux surgery. AIM:To determine the use of proton pump inhibitors and H2 -re...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/apt.13230

    authors： Lødrup A,Pottegård A,Hallas J,Bytzer P

    更新日期：2015-07-01 00:00:00

  • A United States multicentre trial of dual and proton pump inhibitor-based triple therapies for Helicobacter pylori.

    abstract：BACKGROUND:One-week proton pump inhibitor-based triple therapies are very popular in the US despite limited US data documenting efficacy. We assessed 1-week proton pump inhibitor triple therapies for Helicobacter pylori, and compared them to dual antibiotic therapies (to assess benefit of omeprazole) and to omeprazole-...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 临床试验,杂志文章,多中心研究,随机对照试验

    doi：10.1046/j.1365-2036.1997.00230.x

    authors： Laine L,Frantz JE,Baker A,Neil GA

    更新日期：1997-10-01 00:00:00

  • Indomethacin-induced gastric antral damage in hamsters: are neutrophils involved?

    abstract：BACKGROUND:A direct role for neutrophils in the pathophysiology of indomethacin-induced gastric damage is controversial. Therefore, such damage was evaluated in hamsters. METHODS:Gastric antral damage was evaluated 4 h after the oro-gastric administration of indomethacin (30 mg/kg). Prior to indomethacin, hamsters wer...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1046/j.1365-2036.1999.00444.x

    authors： Fitzpatrick LR,Sakurai K,Le T

    更新日期：1999-02-01 00:00:00

  • A comparison of the gut microbiome between long-term users and non-users of proton pump inhibitors.

    abstract：BACKGROUND:Proton pump inhibitor (PPI) use is associated with an increased risk of Clostridium difficile infection (CDI), though the mechanism is unclear. PPI induced alterations to the gut microbiome may facilitate the emergence of CDI, though the effects of PPIs on gut microbiota are not well characterised. [Correcti...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/apt.13568

    authors： Clooney AG,Bernstein CN,Leslie WD,Vagianos K,Sargent M,Laserna-Mendieta EJ,Claesson MJ,Targownik LE

    更新日期：2016-05-01 00:00:00

  • Assessment of concordance of symptom reflux association tests in ambulatory pH monitoring.

    abstract：BACKGROUND:Both simple proportions and statistical tests are utilised for symptom-reflux association. We systematically compared three such tests in a clinical setting. AIM:To compare the three commonly used symptom reflux association tests in a large cohort of patients undergoing ambulatory pH monitoring for the eval...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/j.1365-2036.2012.05066.x

    authors： Kushnir VM,Sathyamurthy A,Drapekin J,Gaddam S,Sayuk GS,Gyawali CP

    更新日期：2012-05-01 00:00:00

  • Long-term use of acid suppression started inappropriately during hospitalization.

    abstract：BACKGROUND:Practitioners routinely misuse acid suppression medications on general medical floors and inappropriately continue the drug at discharge. AIMS:To: (i) retrospectively study the appropriateness of acid suppression use on the general medical floors; (ii) characterize the patient population discharged on unnec...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/j.1365-2036.2005.02454.x

    authors： Zink DA,Pohlman M,Barnes M,Cannon ME

    更新日期：2005-05-15 00:00:00

  • Dyspepsia workload in urban general practice and implications of the British Society of Gastroenterology Dyspepsia guidelines (1996).

    abstract：AIM:To define the characteristics of patients consulting with active dyspeptic symptoms in urban general practice, and to consider the implications of applying the British Society of Gastroenterology Dyspepsia management guidelines. DESIGN:Prospective observational study over a period of 12 months. SETTING:Two multip...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1046/j.1365-2036.2000.00728.x

    authors： Bodger K,Eastwood PG,Manning SI,Daly MJ,Heatley RV

    更新日期：2000-04-01 00:00:00